BAYN logo

Bayer Aktiengesellschaft Stock Price

XTRA:BAYN Community·€29.9b Market Cap
  • 3 Narratives written by author
  • 1 Comments on narratives written by author
  • 247 Fair Values set on narratives written by author

BAYN Share Price Performance

€30.49
11.20 (58.07%)
€29.57
Fair Value
€30.49
11.20 (58.07%)
3.1% overvalued intrinsic discount
€29.57
Fair Value
Price €30.49
AnalystConsensusTarget €29.57
AnalystHighTarget €39.00
AnalystLowTarget €23.00

BAYN Community Narratives

AnalystConsensusTarget·
Fair Value €29.57 3.1% overvalued intrinsic discount

Crop Science And Pharmaceuticals Will Thrive On Favorable Trends

1users have liked this narrative
1users have commented on this narrative
147users have followed this narrative
AnalystHighTarget·
Fair Value €36.67 16.9% undervalued intrinsic discount

Sustainable Farming And Rising Healthcare Will Fuel Expansion

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AnalystLowTarget·
Fair Value €23 32.5% overvalued intrinsic discount

Crop Science And Pharmaceuticals Will Suffer Under Mounting Liabilities

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Trending Discussion

Updated Narratives

BAYN logo

BAYN: Future Litigation Decisions And Agriculture Spin-Out Will Guide Shares

Fair Value: €29.57 3.1% overvalued intrinsic discount
147 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative
BAYN logo

Crop Science And Pharmaceuticals Will Suffer Under Mounting Liabilities

Fair Value: €23 32.5% overvalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BAYN logo

Sustainable Farming And Rising Healthcare Will Fuel Expansion

Fair Value: €36.67 16.9% undervalued intrinsic discount
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with moderate growth potential.

1 Risk
4 Rewards

Bayer Aktiengesellschaft Key Details

€45.9b

Revenue

€19.6b

Cost of Revenue

€26.3b

Gross Profit

€26.5b

Other Expenses

-€198.0m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 25, 2026
-0.20
57.31%
-0.43%
133.5%
View Full Analysis

About BAYN

Founded
1863
Employees
88502
CEO
William Anderson
WebsiteView website
www.bayer.com

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, pain and cardiovascular risk prevention products, digestive health products, allergy products, and cold and cough products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Recent BAYN News & Updates

Recent updates

No updates